Budesonide/Formoterol fumarate dihydrate
Phase 3Small molecule
Budesonide/Formoterol fumarate dihydrate is one of 21 small molecule programs targeting Asthma. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Cinqair
TevaPreclinical
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Budesonide/Formoterol fumarate dihydrate
KKindeva Drug Delivery
Phase 3
Atrovent
Boehringer IngelheimPreclinical
Arcoxia
NovartisPreclinical
Symbicort
AstraZenecaPreclinical
Atrovent
Boehringer IngelheimPreclinical
Aciphex
Akero TherapeuticsPreclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Tylenol
KKenvue Brands
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- KKindeva Drug Delivery